LAUNXP BIOMEDICAL CO., LTD. (6876) Stock Statistics & Valuation Metrics
Total Valuation
LAUNXP BIOMEDICAL CO., LTD. has a market cap or net worth of TWD 888.66M. The enterprise value is ―.
- Market Cap
- TWD 888.66M
- Enterprise Value
- ―
Share Statistics
LAUNXP BIOMEDICAL CO., LTD. has 70,528,540 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 70,528,540
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
LAUNXP BIOMEDICAL CO., LTD.’s return on equity (ROE) is -0.44 and return on invested capital (ROIC) is -40.90%.
- Return on Equity (ROE)
- -0.44
- Return on Assets (ROA)
- -0.27
- Return on Invested Capital (ROIC)
- -40.90%
- Return on Capital Employed (ROCE)
- -0.42
- Revenue Per Employee
- 0
- Profits Per Employee
- -3.14M
- Employee Count
- 35
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of LAUNXP BIOMEDICAL CO., LTD. is -1.77. LAUNXP BIOMEDICAL CO., LTD.’s PEG ratio is -0.02.
- PE Ratio
- -1.77
- PS Ratio
- 1352.14
- PB Ratio
- 2.23
- Price to FCF
- -7.50
- Price to Operating Cash Flow
- -6.43
- PEG Ratio
- -0.02
Income Statement
In the last 12 months, LAUNXP BIOMEDICAL CO., LTD. had revenue of 0 and earned -110.01M in profits. Earnings per share was -2.78.
- Revenue
- 0
- Gross Profit
- -2.52M
- Operating Income
- -110.93M
- Pretax Income
- -110.01M
- Net Income
- -110.01M
- EBITDA
- -108.40M
- Earnings Per Share (EPS)
- -2.78
Cash Flow
In the last 12 months, operating cash flow was -127.98M and capital expenditures -1.86M, giving a free cash flow of -129.84M billion.
- Operating Cash Flow
- -127.98M
- Free Cash Flow
- -129.84M
- Free Cash Flow per Share
- -2.21
Dividends & Yields
LAUNXP BIOMEDICAL CO., LTD. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -13.34%
- Earnings Yield
- -54.60%
Stock Price Statistics
- Beta
- 0.21
- 52-Week Price Change
- -45.34%
- 50-Day Moving Average
- ―
- 200-Day Moving Average
- ―
- Relative Strength Index (RSI)
- 30.62
- Average Volume (3m)
- 309.21K
Financial Position
LAUNXP BIOMEDICAL CO., LTD. as a current ratio of 0.68, with Debt / Equity ratio of 7.78%
- Current Ratio
- 0.68
- Quick Ratio
- 0.68
- Debt to Market Cap
- 0.02
- Net Debt to EBITDA
- 0.28
- Interest Coverage Ratio
- -186.12
Taxes
In the past 12 months, LAUNXP BIOMEDICAL CO., LTD. has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
LAUNXP BIOMEDICAL CO., LTD. EV to EBITDA ratio is -4.92, with an EV/FCF ratio of -4.81.
- EV to Sales
- 868.24
- EV to EBITDA
- -4.92
- EV to Free Cash Flow
- -4.81
- EV to Operating Cash Flow
- -4.88
Balance Sheet
LAUNXP BIOMEDICAL CO., LTD. has TWD 455.28M in cash and marketable securities with TWD 6.87M in debt, giving a net cash position of TWD 448.41M billion.
- Cash & Marketable Securities
- TWD 455.28M
- Total Debt
- TWD 6.87M
- Net Cash
- TWD 448.41M
- Net Cash Per Share
- TWD 6.36
- Tangible Book Value Per Share
- TWD 6.03
Margins
Gross margin is -158.33%, with operating margin of -18183.33%, and net profit margin of -62429.44%.
- Gross Margin
- -158.33%
- Operating Margin
- -18183.33%
- Pretax Margin
- -62429.44%
- Net Profit Margin
- -62429.44%
- EBITDA Margin
- -17652.78%
- EBIT Margin
- -18183.33%
Analyst Forecast
The average price target for LAUNXP BIOMEDICAL CO., LTD. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -163.15%
